Navigation Links
EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors
Date:9/1/2010

EUSA Pharma Announces the Appointment of Stephen A. Stamp to... -- OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors

 

OXFORD, England and LANGHORNE, Pennsylvania, September 1, 2010 /PRNewswire/ -- EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company's Board as an independent Non-Executive Director.

Mr Stamp has extensive experience of the specialty pharmaceutical sector having previously held Board-level roles at Xanodyne Pharmaceuticals Inc. and Shire Pharmaceuticals Plc, and most recently as Chief Financial Officer of K-V Pharmaceutical Company. Mr Stamp has considerable financial expertise developed during a career spanning over 25 years, including more than 10 years in corporate finance and investment banking. He is an Associate Member of the Institute of Chartered Accountants.

"I want to warmly welcome Stephen to EUSA Pharma," said Rolf Stahel, EUSA Pharma's Chairman. "Since its foundation four years ago, EUSA has established itself as a successful transatlantic specialty pharma business, and is now entering its next phase of rapid and profitable growth. Stephen's financial expertise, and history of success in our industry, will prove an important asset as we transition EUSA into one of the most successful companies in its field."

Commenting on his appointment, Stephen A. Stamp said, "Having witnessed EUSA's impressive growth, I am excited to be helping the company achieve its ambitious plans. Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company's continued rapid development."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and spread of prostate cancer and Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 80 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

Contacts Bryan Morton Chief Executive EUSA Pharma Tel: +44(0)1865-784255 Rob Budge RJB Communications Tel: +44(0)1865-760969 Mobile: +44(0)7710-741241
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
2. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
3. Reportlinker Adds Advances in Biopharmaceutical Technology in China
4. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
5. Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey
6. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
7. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
8. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
9. K-V Pharmaceutical Company Engages BDO USA, LLP as Independent Registered Accountants
10. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
11. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016   ... an SNNLive Video Interview with Dr. Nader Pourhassan ... a biotechnology company focused on the clinical development and ... and prevention of HIV infection, according to the company,s ... was recorded on Tuesday, June 7 th , 2016, ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... (PRWEB) , ... June 22, 2016 , ... ... at placing a spotlight on immigrant achievements and contributions to North Texas and ... most important contributors from the immigrant community to the civic and economic vitality ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):